Please assess the completion status of the following clinical trial:

Trial Title: Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- High-risk biopsy-proven treatment-naïve prostate adenocarcinoma (Gleason score ≥ 8 and/or serum PSA \> 20)~Exclusion Criteria:~* Inability to tolerate or undergo PET/MRI~* Previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, Castleman's disease, etc.)~* Recurrent prostate adenocarcinoma~* Known visceral, osseous, or extrapelvic metastases prior to fluciclovine-PET/MRI~* Known allergy to glucagon or gadolinium-based contrast

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [18F] Fluciclovine PET/MRI (Type: EXPERIMENTAL): \[18F\] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).